Updated:
ITI Group
ITI Group was founded in 1991 by Sudhir Valia, a chartered accountant who became a pivotal figure in the creation of Sun Pharmaceuticals, India's largest...
ITI Group
ITI Group was founded in 1991 by Sudhir Valia, a chartered accountant who became a pivotal figure in the creation of Sun Pharmaceuticals, India's largest drugmaker by market capitalization. Valia is the brother-in-law of Sun Pharma founder Dilip Shanghvi, and their intertwined business history forms the financial bedrock of ITI. The group is anchored by The Investment Trust of India Limited, a publicly traded holding entity chaired by Chintan Vijay Valia, Sudhir Valia's son-in-law. This corporate structure—rather than a pure single-family office—embeds the family's investment activities within regulated financial services businesses that serve external clients as well. The group operates through three distinct verticals. ITI Mutual Fund competes in India's retail asset management market. ITI Capital provides institutional broking and investment banking services, including margin financing and equity derivatives. The ITI Growth Opportunities Fund, managed by Mohit Gulati, represents the private investing arm, targeting early-to-growth-stage companies in fintech, consumer tech, and adjacent digital infrastructure. The fund has backed companies including BharatPe, a merchant payments network, and has historically sought deal flow from the family's vast corporate network. Investment activity is concentrated in India, with deal sourcing rooted in the Mumbai financial ecosystem. Beyond financial services, the group holds significant real estate assets through Suraksha Realty, including residential projects in Mumbai, Bangalore, and the Wish Town township development in Noida. These property holdings serve as both a store of intergenerational wealth and an active development business. The firm's total professionals and precise assets under management or deployment remain undisclosed. In 2023, regulatory filings showed ITI Mutual Fund managing over $1 billion in public assets, but this figure excludes the private direct-investment book and real estate portfolio, making a consolidated AUM inference unreliable. ITI's architecture is structurally distinct from most Indian single-family offices because it operates through regulated, client-facing financial institutions rather than a private investment company. This model blurs the line between family office and public asset manager, creating both regulatory obligations and revenue from third-party fees. The firms's successor generation is already in place: Chintan Valia runs the listed holding company, while the growth fund operates with a non-family CIO, suggesting a professionalized governance model that separates oversight from investment execution.
General information
Firm type
Corporate Investor
Year founded
1991
AUM
Undisclosed
Location
Region
Asia
Country
India
City
Mumbai
Corporate office
ITI House, 36 Dr. R. K. Shirodkar Marg, Parel, Mumbai, Maharashtra 400012, India
Principals
Sudhir Valia
Founder, Promoter
Chintan Vijay Valia
Chairman, The Investment Trust of India Limited
Mohit Gulati
Managing Partner & CIO, ITI Growth Opportunities Fund
Dilip Shanghvi
Family Member, Co-promoter of Sun Pharmaceuticals
Sector focus
Frequently asked questions
Who makes investment decisions at ITI Group?
The ITI Growth Opportunities Fund is managed by Mohit Gulati, the firm's Managing Partner and Chief Investment Officer, who is a non-family professional. Mutual fund and broking operations fall under regulated entities where investment committees operate within SEBI guidelines. Oversight rests with Chintan Vijay Valia as Chairman of The Investment Trust of India Limited, while founder Sudhir Valia maintains strategic influence across the group's capital allocation.
How is ITI Group related to Sun Pharmaceuticals?
Sudhir Valia, ITI's founder, is the brother-in-law of Sun Pharma founder Dilip Shanghvi and served as a co-promoter of the drugmaker. Sun Pharma's massive market capitalization forms the foundational wealth behind the Valia-Shanghvi family interests. However, ITI Group operates as a separate corporate entity rather than a consolidated family office for Sun Pharma's founders.
Does ITI Group invest in public markets or only private companies?
ITI operates across both markets. Its mutual fund arm manages public equity and debt funds for retail and institutional investors. ITI Capital handles public-market broking and margin financing. The private investing arm, ITI Growth Opportunities Fund, makes direct equity investments in private companies, typically at growth stage.
What is the relationship between ITI Group and Suraksha Realty?
Suraksha Realty is the group's property development arm, founded by Sudhir Valia. It holds residential and commercial projects across Mumbai, Bangalore, and Noida. These real estate assets operate alongside—but separately from—the financial services businesses, functioning as a long-term intergenerational wealth vehicle.
Does ITI Group accept outside capital or only invest proprietary family funds?
ITI accepts significant outside capital. The mutual fund operates as a public asset manager. The ITI Growth Opportunities Fund has raised external LP capital for its venture investments. This hybrid model—combining proprietary family balance sheet with third-party client assets—is a defining characteristic that distinguishes ITI from a pure single-family office.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: